

7th August, 2019

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that Cipla Limited ("the Company") has signed a definitive agreement today to acquire the minority stake of Eight Roads Investment Mauritius II Limited (earlier known as FIL Capital Investments (Mauritius) II Limited) in Cipla Health Limited, subsidiary of the Company.

The details as required under the SEBI Listing Regulations are enclosed as Annexure – I.

Thanking you.

Yours faithfully,
For **Cipla Limited**



Rajendra Chopra
Company Secretary

Encl: as above

Annexure - I

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.;	Cipla Health Limited (CHL). It has a turnover of Rs. 14,782.80 lakhs for the financial year ended 31 st March 2019.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Acquisition does not fall within the purview of related party transactions. None of the promoter / promoter group / promoter group companies are interested in the acquisition.
c)	Industry to which the entity being acquired belongs;	Consumer Healthcare/ OTC Industry
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	<ul style="list-style-type: none"> Cipla Health Ltd. (CHL) was created in FY'16 with the aim of making a difference to the everyday lives of consumers through simplified and innovative solutions in the consumer healthcare segment. CHL grew steadily since its inception through a strong spirit of partnership between Cipla Ltd, CHL and Eight Roads Investment Mauritius II limited (formerly known as FIL Capital Investments (Mauritius) II limited). Eight Roads held minority ownership in CHL through two rounds of investment in April 2016 and August 2018. In a mutually agreed and planned transition, Cipla Ltd and Eight Roads have today signed the definitive agreement for Cipla Ltd to acquire the minority stake of Eight Roads in CHL, thereby giving Cipla Ltd 100% ownership interest of CHL. The development comes in view of Cipla's growing focus on consumer-facing products, and the high potential for synergy between the CHL and Cipla in-house portfolios. In FY'18-19, CHL's flagship smoking cessation brand, Nicotex, remained the undisputed market leader in its category; its Cofsils franchise saw increased market share and brand extension across trade channels; its ActivKids ImmunoBoosters became the first Cipla product to be available in modern trade, e-commerce, high-end grocers and B2B channels; its probiotic brand, UnoBiotics, became the #1 player in the LRGG (Lactobacillus Rhamnosus GG) market within 15 months of launch
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	NA
f)	Indicative time-period for completion of the acquisition;	The transaction is expected to be completed within a month
g)	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration
h)	Cost of acquisition or the price at which the shares are acquired	Cash consideration of Rs. 3500,000,000/- (Rupees Three Thousand Five Hundred Million Only) to be paid on closing of the transaction

hc

i)	Percentage of shareholding / control acquired and / or number of shares acquired	5,34,658 Series A Compulsory Convertible Preference Shares (CCPS) of Rs.50/-each, 33,039 Series A1 Compulsory Convertible Preference Shares of Rs 50/- each and 1000 Equity Shares of Rs.10/- each, representing 26.16% stake, on a fully diluted basis, in the Company
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	Cipla Health Limited was incorporated on 27 th August 2015 in India. It is engaged in the business of developing, manufacturing, marketing and distribution of over the counter consumer health care products. Presently it has operations only in India. CHL's turnover for FY 19 is Rs 14,782.80 lakhs, FY 18 is Rs 12,017.87 lakhs, FY 17 is Rs 9,994.20 lakhs.

